



ILTOO Pharma Announces Managed Access Program for ALS Patients

Paris, 14 September 2023

ILTOO Pharma SAS announces the initiation of Managed Access Programs for the compassionate treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS) with ILT-101, the company's lead drug. The initiation of Managed Access Programs is a very significant step for ILTOO Pharma and details of the programs are now available on the company's website.

Since being founded in 2012, ILTOO Pharma has been working to establish clinical evidence and a regulatory basis for our treatments. Initial studies such as TRANSREG in 2013, LUPIL2 (SLE Lupus) in 2017, along with two pivotal studies in ALS, IMODALS in 2015 and MIROCALS initiated in 2017, together involving more than 400 patients to date, have all confirmed that ILT-101 represents a ground-breaking treatment for patients with auto- and neuro-immune and inflammatory diseases, particularly for ALS.

CEO of ILTOO, Jeff Lyons, said, "We are now making ILT-101 available to a wider group of ALS patients. To date, we have been collaborating with regulatory agencies to provide access to ILT-101 for European and US patients on a named-patient basis. This announcement is the next significant step for the company and we will continue to make our treatment more available to ALS patients worldwide."

Chairman of ILTOO, José Achache, commented, "Announcing the Managed Access Programs is a great achievement for the company. Providing compassionate treatment for patients is not only gratifying progress, but also a strong vindication of the company's platform treatment aimed at restoring the balance in the body's immune system by stimulating regulatory T-cells in the body. This is key to treating ALS as well as many other auto- and neuro-immune and inflammatory conditions."

About Amyotrophic lateral sclerosis:

Amyotrophic lateral sclerosis (ALS), also known as Charcot's disease or Lou Gehrig's disease, is an adult-onset motor neuron disease and is usually diagnosed between the ages of 40 and 70. It is a life-limiting neurodegenerative disease that affects about 42,000 patients in Europe and 32,000 patients in the US. There is currently no cure for ALS and no effective treatment to stop or reverse its progression.

About ILT-101:

ILT-101 is the lead drug of ILTOO Pharma SAS. The medication has been formulated to be easy to use and more suitable for long-term treatment, with a unique formulation that enables stability over a period of 36 months and better fit to patient needs. Future plans include making ILT-101 available in a self-injector. The drug has been developed to treat a wide range of diseases including auto-immune and inflammatory diseases and certain central nervous system conditions.

About ILTOO Pharma:

ILTOO Pharma SAS is dedicated to the development of immunotherapies with IL-2_{LD} for the treatment of auto-immune, neuro-immune and inflammatory disorders. The company has been focused for more than a decade on pioneering the use of Interleukin 2 at low dose, referred to as IL-2_{LD}, to treat auto-immune, neuro-immune as well as inflammatory diseases by stimulating Regulatory T-cells (Tregs) in the body.

The company is based in central Paris and benefits from collaborations with the Pitié-Salpêtrière Hospital and Sorbonne University.

For further information, please visit our website at: www.iltoopharma.com